Enrico Picozza
Partner
Get their honest, personalized take on your startup.
Sign in to pitch Enrico →At a glance
- Full Name
- Enrico Picozza
- Title
- Partner
- Firm
- HLM Investment Partners (formerly HLM Venture Partners)
- Firm Type
- Healthcare-focused venture capital firm
- Investment Stage
- Seed, Series A, Series B, and Growth Equity (the original stub's "Seed Round / Angel" label understates HLM's multi-stage healthcare VC mandate)
- Check Size
- Not publicly disclosed
- Target Company Profile
- Capital-efficient, patient-centric, technology-enabled healthcare companies with operational traction, positioned at growth inflection points within large, fragmented markets and led by strong management teams
- Sector Focus
- Healthcare exclusively — health tech, behavioral health, patient engagement, provider/care-access solutions, value-based care, diagnostics, and life sciences
- Geographic Focus
- Primarily United States
- Location
- Waltham, Massachusetts (Greater Boston)
Background
Enrico Picozza is a Partner at HLM Investment Partners, a Waltham, Massachusetts–based healthcare-focused venture capital firm that manages roughly $400 million and has made over 100 healthcare investments. The firm rebranded from "HLM Venture Partners" to "HLM Investment Partners" and, as of August 2025, was raising its sixth fund (HLM Investment Partners VI, L.P.) alongside fellow partners Ed Cahill, Michael Ludwig, Joseph Mayer, M.D., and Vin Fabiani.
Picozza is described by the firm as a pioneer in the life sciences with more than 30 years of experience identifying, developing, and commercializing disruptive technologies. Earlier in his career he held key leadership positions at PerkinElmer Inc. / Applied Biosystems, Inc., where he played a pivotal role in the development and commercialization of PCR (polymerase chain reaction), the DNA-amplification technology that transformed molecular biology, diagnostics, and genomics. For this work he was recognized by the Smithsonian Institution, and he holds nine U.S. patents.
Before joining HLM, Picozza was a serial entrepreneur who co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point-of-care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer (the company was later acquired). He completed both his undergraduate and graduate studies at the University of Connecticut, earning a master's degree in molecular and cell biology.
At HLM, Picozza has served as a director or board observer across a broad set of digital-health and healthcare-services companies, reflecting the firm's thesis around technology-enabled care delivery and value-based models.
Investment Thesis & Focus
- Invests exclusively in healthcare, favoring "capital-efficient, patient-centric, and technology-enabled" companies.
- Targets companies operating in large, fragmented markets with strong management teams that leverage technology to expand care access and enable value-based care.
- Active across Seed, Series A, Series B, and Growth Equity stages rather than a single entry point.
- Emphasis areas include behavioral health, patient engagement, provider-shortage solutions, and digital health infrastructure, plus diagnostics/life-sciences given Picozza's scientific background.
- Looks for operational traction and a clear growth inflection point, not just early concepts.
Notable Investments
- AbleTo — virtual behavioral health provider; board director (acquired by Optum/UnitedHealth Group).
- mPulse Mobile — conversational AI / patient-engagement platform; director/board observer (recapitalized by PSG).
- RubiconMD — eConsult / specialty-care access platform (acquired by Oak Street Health / CVS).
- NeuroFlow — behavioral health integration and measurement-based care; board director.
- Wayspring — value-based care for substance use disorder; board director.
- HarmonyCares — in-home primary and complex care for medically vulnerable patients; board director.
- Elligent Health — healthcare technology company; board director.
- bWell Connected Health — digital health platform; board director.
- Fuze Health — board observer.
- OnShift — workforce management for senior care; former board observer.
- Transcend Medical — ophthalmic medical device company (acquired by Alcon).
- HTS Biosystems — co-founded; drug discovery / diagnostics platform (acquired).
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.